Relationship between fecal calprotectin, anti-Saccharomyces cerevisiae antibodies and other markers of disease activity in patients with spondyloarthritis

• Published in: Reumatologia clinica Vol. 15; no. 6; pp. 360 - 362
• Main Authors: Moreno Martínez, María José, Moreno Ramos, Manuel José, Linares Ferrando, Luis Francisco
• Format: Journal Article
• Language: English; Spanish
• Published: Spain 01.11.2019
• Subjects: Adult; Antibodies, Fungal - blood; Biomarkers - analysis; C-Reactive Protein - analysis; Feces - chemistry; Humans; Leukocyte L1 Antigen Complex - analysis; Middle Aged; Saccharomyces cerevisiae - immunology; Spondylarthritis - blood; Spondylarthritis - diagnosis; Spondylarthritis - metabolism; Antiinflamatorios; Inflamación; Calprotectina; Anti-inflammatory drugs; Calprotectin; Inflammation; Espondiloartritis; Spondyloarthritis
• ISSN: 1885-1398; 2173-5743
• DOI: 10.1016/j.reuma.2017.11.013

To assess the relationship between the increase of fecal calprotectin, anti-Saccharomyces cerevisiae antibodies (ASCA) and disease markers in a group of patients with spondyloarthritis. We evaluated patients who were at least 18-years-old and met the Assessment in Spondyloarthritis International Society (ASAS) criteria for spondyloarthritis or the New York modified criteria. We analyzed activity criteria, physical function, analytical criteria (human leukocyte antigen [HLA] B27, fecal calprotectin, presence of ASCA, among others) and demographic data. We included 33 patients. All but one patient had normal ASCA values. We found statistical significance in the correlation of calprotectin with C-reactive protein (CRP) but not with other parameters. We also found a relationship between calprotectin levels and nonsteroidal anti-inflammatory drug (NSAID) intake (P=.001). We found no relationship between CRP levels and NSAID use. After discontinuation of NSAIDs for one month, we found no significant differences in calprotectin levels (P=.9). Fecal calprotectin is elevated in patients with spondyloarthritis and correlates positively with CRP. Level of fecal calprotectin is not altered by NSAID use. The amount of ASCA present does not change and does not correlate with any clinical parameters in the study population.